Heron Therapeutics(HRTX) Prnewswire·2025-02-27 12:45Core Insights - Heron Therapeutics reported a milestone year in 2024, achieving positive net income in Q4 and a full-year net revenue increase of 14% year-over-year, totaling $144.2 million [2][5][27] - The company is positioned for future growth with its product ZYNRELEF, which has expanded label indications and is expected to benefit from new promotional efforts and regulatory approvals [2][6] Financial Performance - Q4 2024 GAAP net income was $3.6 million, compared to a net loss of $10.7 million in Q4 2023 [5][27] - Full-year 2024 adjusted EBITDA was $8.6 million, with a total operating revenue of $144.3 million, up from $127.0 million in 2023 [5][27] - The company generated Q4 2024 net revenue of $40.8 million, a 19.1% increase from $34.2 million in Q4 2023 [8][27] Product Highlights - ZYNRELEF generated Q4 2024 net revenue of $8.5 million, with expanded indications covering approximately 17 million annual procedures [5][6] - The launch of the ZYNRELEF Vial Access Needle (VAN) is expected to simplify preparation and reduce withdrawal time significantly [6] - The U.S. District Court ruled in favor of Heron in a patent lawsuit, upholding the validity of CINVANTI patents, which expire in 2035 [5] Financial Guidance - For 2025, the company projects net revenue between $153 million and $163 million, with adjusted EBITDA ranging from $0 million to $8 million [3]